Linked Life Data

17140351

Source:http://linkedlifedata.com/resource/pubmed/id/17140351

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2006-12-4
pubmed:abstractText
Antimicrobial resistance among Gram-positive organisms continues to increase and has reached epidemic proportions in numerous countries. Telavancin is a semisynthetic lipoglycopeptide with a dual mechanism of action that involves the inhibition of cell-wall synthesis and disruption of bacterial cell-membrane barrier functions. Telavancin exhibits a rapid bactericidal activity against Staphylococcus aureus. It is also active against coagulase-negative staphylococci, enterococci, streptococci and various anaerobic Gram-positive organisms. Telavancin has a prolonged postantibiotic effect and distributes well into cutaneous and pulmonary tissues. Furthermore, it has a low potential for development of resistance and is well tolerated. The overall incidence of adverse events in patients receiving telavancin was similar to that observed with standard therapy and recent data from preliminary clinical trials have demonstrated similar efficacy to standard therapy in the treatment of complicated skin and skin-structure infections. Therefore, telavancin is a promising new antimicrobial agent for the treatment of infections caused by resistant Gram-positive pathogens.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1744-8336
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
743-9
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Telavancin: a new lipoglycopeptide with multiple mechanisms of action.
pubmed:affiliation
Duke University Medical Center, Duke Clinical Research Institute, Division of Infectious Diseases, 2400 Pratt Street, Rm 7543, Durham, NC 27710, USA. kanaf001@mc.duke.edu
pubmed:publicationType
Journal Article, Review